Value in Health Regional Issues Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis Tanita Thaweethamcharoen, PhD, Rungpetch Sakulbumrungsil, PhD, Cherdchai Nopmaneejumruslers, MD, Somkiat Vasuvattakul, MD Value in Health Regional Issues Volume 3, Pages 44-49 (May 2014) DOI: 10.1016/j.vhri.2014.01.001 Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 1 Schematic representation of Markov model. CV, cardiovascular; nCV, noncardiovascular; HD, hemodialysis; HDCV, hemodialysis and cardiovascular disease. Value in Health Regional Issues 2014 3, 44-49DOI: (10.1016/j.vhri.2014.01.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 2 Cost-effectiveness acceptability curve of the different Hb levels compared with the Hb levels <9 g/dl. Hb, hemoglobin. Value in Health Regional Issues 2014 3, 44-49DOI: (10.1016/j.vhri.2014.01.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions